JP2016513128A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513128A5
JP2016513128A5 JP2015559275A JP2015559275A JP2016513128A5 JP 2016513128 A5 JP2016513128 A5 JP 2016513128A5 JP 2015559275 A JP2015559275 A JP 2015559275A JP 2015559275 A JP2015559275 A JP 2015559275A JP 2016513128 A5 JP2016513128 A5 JP 2016513128A5
Authority
JP
Japan
Prior art keywords
compound according
group
atoms
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015559275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513128A (ja
JP6356160B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/018380 external-priority patent/WO2014131023A1/en
Publication of JP2016513128A publication Critical patent/JP2016513128A/ja
Publication of JP2016513128A5 publication Critical patent/JP2016513128A5/ja
Application granted granted Critical
Publication of JP6356160B2 publication Critical patent/JP6356160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015559275A 2013-02-25 2014-02-25 ネオセプチン:低分子アジュバント Expired - Fee Related JP6356160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768712P 2013-02-25 2013-02-25
US61/768,712 2013-02-25
PCT/US2014/018380 WO2014131023A1 (en) 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants

Publications (3)

Publication Number Publication Date
JP2016513128A JP2016513128A (ja) 2016-05-12
JP2016513128A5 true JP2016513128A5 (https=) 2017-04-06
JP6356160B2 JP6356160B2 (ja) 2018-07-11

Family

ID=51391916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559275A Expired - Fee Related JP6356160B2 (ja) 2013-02-25 2014-02-25 ネオセプチン:低分子アジュバント

Country Status (7)

Country Link
US (1) US9649373B2 (https=)
EP (1) EP2958889B1 (https=)
JP (1) JP6356160B2 (https=)
CN (1) CN105339346B (https=)
AU (1) AU2014218598B2 (https=)
CA (1) CA2902342C (https=)
WO (1) WO2014131023A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
TWI674258B (zh) 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Dna烷化劑
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
JP7327900B2 (ja) 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ, インコーポレイテッド アジリジン含有dnaアルキル化剤
US20180327364A1 (en) * 2015-11-13 2018-11-15 Brandeis University Mtor inhibitors and methods of use thereof
CA3026178C (en) * 2016-06-29 2024-05-21 The Scripps Research Institute Diprovocims: a new and potent class of tlr agonists
EP3710007A4 (en) 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031083A (en) 1975-10-24 1977-06-21 Yeda Research And Development Co., Ltd. Cephalosporin antibiotics
US4045438A (en) 1975-10-24 1977-08-30 Yeda Research And Development Co. Ltd. Cephalosporin antibiotics
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
CA2611721C (en) * 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
CN101304748A (zh) * 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US20100068150A1 (en) * 2006-07-07 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Selective Caspase Inhibitors
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2391718A2 (en) * 2009-01-30 2011-12-07 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9

Similar Documents

Publication Publication Date Title
JP2016513128A5 (https=)
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
JP2018511647A5 (https=)
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
JP2013510124A5 (https=)
JP2008525417A5 (https=)
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
JP2013510123A5 (https=)
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
RU2018120318A (ru) ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
JP2015516427A5 (https=)
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
JP2013523814A5 (https=)
CL2008003383A1 (es) Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico.
CL2025001760A1 (es) Compuesto quimérico protac, método de preparación del mismo y uso del mismo
AR087212A1 (es) ANTAGONISTAS DE CRTh2
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора